Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Harmony Biosciences Holdings (HRMY) EBIT Margin (2020 - 2025)

Harmony Biosciences Holdings (HRMY) has disclosed EBIT Margin for 6 consecutive years, with 51.17% as the latest value for Q4 2025.

  • Quarterly EBIT Margin fell 7886.0% to 51.17% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 5.2% through Dec 2025, down 2150.0% year-over-year, with the annual reading at 5.2% for FY2025, 2150.0% down from the prior year.
  • EBIT Margin hit 51.17% in Q4 2025 for Harmony Biosciences Holdings, down from 27.35% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 40.25% in Q3 2023 to a low of 51.17% in Q4 2025.
  • Historically, EBIT Margin has averaged 24.72% across 5 years, with a median of 30.69% in 2022.
  • Biggest five-year swings in EBIT Margin: skyrocketed 7279bps in 2021 and later tumbled -7886bps in 2025.
  • Year by year, EBIT Margin stood at 31.39% in 2021, then rose by 18bps to 37.11% in 2022, then plummeted by -36bps to 23.87% in 2023, then grew by 16bps to 27.69% in 2024, then crashed by -285bps to 51.17% in 2025.
  • Business Quant data shows EBIT Margin for HRMY at 51.17% in Q4 2025, 27.35% in Q3 2025, and 24.03% in Q2 2025.